Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.
A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
In the fourth episode of a six-part interview series on immunotherapy, Marc Voigt, CEO and Executive Director of Immutep (ASX ...
News-Medical.Net on MSN4d
Combination immunotherapy improves treatment response for head and neck cancerResearchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...
GlobalData on MSN14d
CStone doses first subject in trial of CS2009 for advanced solid tumoursThe antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.
DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ ...
Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in ...
In November 2024, CStone presented preclinical data for CS2009 at the 39th SITC Annual Meeting. These results show that CS2009 exhibits superior anti-tumor activity compared to potential competitors, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback